Matthew D. Blunt
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review.
Journal: Pediatric blood & cancer
Published: March 04, 2026
CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A.
Journal: Clinical and experimental immunology
Published: November 07, 2025
CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.
Journal: Immunotherapy advances
Published: April 25, 2025
Modulation of anti-tumour immunity by XPO1 inhibitors.
Journal: Exploration of targeted anti-tumor therapy
Published: January 13, 2025
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells.
Journal: Science advances
Published: August 23, 2024
Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.
Journal: Oncotarget
Published: July 17, 2024
NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity.
Journal: Biomedicines
Published: June 12, 2024
KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.
Journal: Frontiers in oncology
Published: March 20, 2024
Targeting KIR as a novel approach to improve CAR-NK cell function.
Journal: Journal of translational genetics and genomics
Published: January 17, 2024
Harnessing natural killer cell effector function against cancer.
Journal: Immunotherapy advances
Published: September 20, 2023
Last Updated: 09/26/2026